IL243926B - Selectively converted quinoline compounds - Google Patents
Selectively converted quinoline compoundsInfo
- Publication number
- IL243926B IL243926B IL243926A IL24392616A IL243926B IL 243926 B IL243926 B IL 243926B IL 243926 A IL243926 A IL 243926A IL 24392616 A IL24392616 A IL 24392616A IL 243926 B IL243926 B IL 243926B
- Authority
- IL
- Israel
- Prior art keywords
- selectively substituted
- substituted quinoline
- quinoline compounds
- compounds
- selectively
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890858P | 2013-10-14 | 2013-10-14 | |
| PCT/US2014/060412 WO2015057655A1 (en) | 2013-10-14 | 2014-10-14 | Selectively substituted quinoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL243926A0 IL243926A0 (en) | 2016-04-21 |
| IL243926B true IL243926B (en) | 2019-06-30 |
Family
ID=51842880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243926A IL243926B (en) | 2013-10-14 | 2016-02-03 | Selectively converted quinoline compounds |
| IL267031A IL267031B (en) | 2013-10-14 | 2019-06-02 | Selectively converted quinoline compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267031A IL267031B (en) | 2013-10-14 | 2019-06-02 | Selectively converted quinoline compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9663486B2 (https=) |
| EP (1) | EP3057948B1 (https=) |
| JP (1) | JP6483666B2 (https=) |
| KR (1) | KR102365952B1 (https=) |
| CN (2) | CN105636945B (https=) |
| AU (1) | AU2014334551B2 (https=) |
| BR (1) | BR112016008378B1 (https=) |
| CA (1) | CA2920791C (https=) |
| ES (1) | ES2670550T3 (https=) |
| IL (2) | IL243926B (https=) |
| MX (1) | MX363708B (https=) |
| RU (1) | RU2671496C2 (https=) |
| WO (1) | WO2015057655A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA027968B1 (ru) * | 2011-12-22 | 2017-09-29 | Мерк Патент Гмбх | Гетероциклические карбоксамиды в качестве модуляторов активности киназ |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| SG10202103278TA (en) | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| EP4198031A1 (en) * | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| CR20190119A (es) | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| ES2965044T3 (es) * | 2017-07-18 | 2024-04-10 | Merck Patent Gmbh | Antagonistas de TLR7/8 y sus usos |
| CN111511729A (zh) * | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP2021507889A (ja) * | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| KR20210018818A (ko) | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| US20220363667A1 (en) * | 2018-07-17 | 2022-11-17 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| CA3108099A1 (en) * | 2018-07-31 | 2020-02-06 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| WO2020048595A1 (en) * | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| JP7367004B2 (ja) * | 2018-09-06 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のピラゾロビリジン化合物 |
| EP3847165A1 (en) * | 2018-09-07 | 2021-07-14 | F. Hoffmann-La Roche AG | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US10689360B1 (en) | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| AU2020250468A1 (en) * | 2019-03-29 | 2021-11-04 | Kinki University | Use of T-type calcium channel blocker for treating pruritus |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| JP2022546863A (ja) | 2019-09-10 | 2022-11-09 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規キノリン化合物 |
| WO2021052892A1 (en) | 2019-09-16 | 2021-03-25 | F. Hoffmann-La Roche Ag | Piperidinyl amine compounds for the treatment of autoimmune disease |
| JP7307796B2 (ja) | 2019-09-23 | 2023-07-12 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用 |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| WO2021094301A1 (en) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| JP2023502087A (ja) | 2019-11-19 | 2023-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 |
| JP7649306B2 (ja) | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| US12421229B2 (en) | 2019-12-03 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN112649540B9 (zh) * | 2021-01-11 | 2022-02-18 | 中国科学院西北生态环境资源研究院 | 一种类异戊二烯烷烃中姥鲛烷非对映异构体快速分离方法 |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO156828C (no) | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
| IL62783A (en) | 1981-05-04 | 1987-01-30 | Usv Pharma Corp | Antihypertensive 1,4-thiazine,1,4-thiazepine and 1,4-thiazocine compounds,method for the preparation thereof and pharmaceutical compositions containing the same |
| JPS5890511A (ja) | 1981-11-25 | 1983-05-30 | Otsuka Pharmaceut Co Ltd | 抗菌剤 |
| US5358949A (en) | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| JPS6354363A (ja) | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| AU639529B2 (en) | 1987-03-04 | 1993-07-29 | Higuchi, Yoshinari | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| JPH01156960A (ja) * | 1987-09-24 | 1989-06-20 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| JPH08295690A (ja) | 1995-04-26 | 1996-11-12 | Tokuyama Corp | クロメン化合物 |
| WO1998016497A1 (en) | 1996-10-11 | 1998-04-23 | Kowa Co., Ltd. | Novel diamide compounds and drugs containing the same |
| DE19643048A1 (de) | 1996-10-18 | 1998-04-23 | Daimler Benz Ag | Verbindungen und deren Verwendung sowie Verfahren zur Herstellung von flüssigkristallinen Polymeren daraus |
| GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| US6933272B1 (en) | 1998-09-22 | 2005-08-23 | Erik Helmerhorst | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| PL351470A1 (en) | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| DE19936437A1 (de) | 1999-08-03 | 2001-02-08 | Aventis Cropscience Gmbh | Kombinationen aus Herbiziden und Safenern |
| FR2798656B1 (fr) * | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| US6710205B2 (en) | 2000-02-22 | 2004-03-23 | Ono Pharmaceutical Co., Ltd. | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient |
| DE60102137T2 (de) | 2000-03-17 | 2004-10-21 | Bristol Myers Squibb Pharma Co | Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren |
| IL151552A0 (en) | 2000-03-17 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| DE60115069T2 (de) | 2000-09-11 | 2006-08-03 | Chiron Corp., Emeryville | Chinolinonderivate als tyrosin-kinase inhibitoren |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CN1509184A (zh) | 2001-03-19 | 2004-06-30 | �ձ���ҩ��ʽ���� | 止痒剂 |
| US20030055263A1 (en) | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| DE10222166A1 (de) | 2002-05-20 | 2003-12-11 | Fraunhofer Ges Forschung | Chirale Verbindungen und deren Verwendung |
| DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| ATE404537T1 (de) | 2002-08-13 | 2008-08-15 | Shionogi & Co | Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOCHINOLINONE AND ITS USE |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| US20040072802A1 (en) | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
| GB2396154B (en) | 2002-10-15 | 2007-02-28 | Merck Patent Gmbh | 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices |
| EP1594842A1 (en) | 2003-02-22 | 2005-11-16 | MERCK PATENT GmbH | Cyanopyridone derivatives as liquid crystals |
| WO2004083235A2 (en) | 2003-03-19 | 2004-09-30 | Exelixis Inc. | Tie-2 modulators and methods of use |
| CA2523125A1 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| WO2004087835A1 (en) | 2003-04-01 | 2004-10-14 | Merck Patent Gmbh | Chiral polymerizable compounds |
| CN1809357B (zh) * | 2003-06-20 | 2010-12-22 | 科勒制药有限公司 | 小分子Toll样受体(TLR)拮抗剂 |
| MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| WO2005028488A1 (en) | 2003-09-12 | 2005-03-31 | Quatrx Pharmaceuticals Co. | Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels |
| US7211671B2 (en) | 2003-10-01 | 2007-05-01 | Bristol Myers Squibb Company | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| JP2005132834A (ja) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | キノリン誘導体 |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US20050209247A1 (en) | 2003-11-07 | 2005-09-22 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| TWI316955B (en) | 2003-11-19 | 2009-11-11 | Chisso Corp | Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof |
| JP2007520527A (ja) | 2004-02-04 | 2007-07-26 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体 |
| RU2006127575A (ru) | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| EP1718306A2 (en) | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| WO2005087217A1 (en) | 2004-03-05 | 2005-09-22 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| EP1756101A2 (en) | 2004-05-17 | 2007-02-28 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| US7514450B2 (en) | 2004-05-19 | 2009-04-07 | Neurosearch A/S | Azabicyclic aryl derivatives |
| GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| EP1831194A4 (en) | 2004-12-21 | 2009-12-02 | Astrazeneca Ab | HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7312181B2 (en) | 2005-04-08 | 2007-12-25 | Cropsolution, Inc. | Acylated thiosemicarbazides as herbicides |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| JP2007045752A (ja) | 2005-08-10 | 2007-02-22 | Takeda Chem Ind Ltd | ５員芳香族複素環誘導体、その製造法および用途 |
| JP2007131765A (ja) | 2005-11-11 | 2007-05-31 | Fujifilm Corp | 液晶性組成物 |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| JP2009524637A (ja) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| PL2044056T3 (pl) | 2006-07-14 | 2013-01-31 | Novartis Ag | Pochodne pirymidyny jako inhibitory ALK-5 |
| EP2057164A1 (en) | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| WO2008063609A2 (en) | 2006-11-17 | 2008-05-29 | Polyera Corporation | Diimide-based semiconductor materials and methods of preparing and using the same |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
| AU2008266856A1 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of PFKFB3 inhibitors with anti-neoplastic activities |
| US8557823B2 (en) | 2007-06-18 | 2013-10-15 | Advanced Cancer Therapeutics, Llc | Family of PFKFB3 inhibitors with anti-neoplastic activities |
| CA2689523A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors derived from benzoxazole arylamides |
| WO2008156715A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
| JP5057056B2 (ja) | 2007-08-03 | 2012-10-24 | Ｊｓｒ株式会社 | 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物 |
| WO2009058730A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Diamido thiazole derivatives as protein kinase inhibitors |
| JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
| CN101440062B (zh) | 2007-11-23 | 2011-09-28 | 齐齐哈尔大学 | N-酰基-8-氨基喹啉衍生物的合成及其作为荧光分子探针的应用 |
| JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
| BRPI0910253A2 (pt) | 2008-03-07 | 2015-09-29 | Hoffmann La Roche | derivados de 2-aminoquinolina |
| JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
| US8980877B2 (en) | 2008-04-15 | 2015-03-17 | Dac S.R.L. | Spirocyclic derivatives as histone deacetylase inhibitors |
| WO2009137081A2 (en) | 2008-05-07 | 2009-11-12 | Massachusetts Institute Of Technology | Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase |
| WO2009139438A1 (ja) | 2008-05-15 | 2009-11-19 | 田辺三菱製薬株式会社 | 光学活性カルボン酸の製造方法 |
| EP2300438A4 (en) | 2008-06-11 | 2012-06-27 | Merck Sharp & Dohme | IMIDAZOLE DERIVATIVES AS FAAH INHIBITORS |
| CN102089278A (zh) | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
| AU2009257795A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of FAAH |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| JP2011528354A (ja) | 2008-07-15 | 2011-11-17 | タイゲン バイオテクノロジー カンパニー，リミテッド | 抗生物質 |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| AU2009279874B2 (en) | 2008-08-04 | 2015-02-12 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
| US20100041891A1 (en) | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
| JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
| JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR073920A1 (es) | 2008-10-23 | 2010-12-09 | Boehringer Ingelheim Int | Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion. |
| JP2012511008A (ja) | 2008-12-05 | 2012-05-17 | 持田製薬株式会社 | ＩＸａ因子阻害薬としてのモルホリノン化合物 |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| CN101759683B (zh) | 2008-12-25 | 2011-12-28 | 哈尔滨誉衡药业股份有限公司 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
| JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する複素環化合物 |
| CN104592219B (zh) | 2009-03-16 | 2017-04-12 | 住友化学株式会社 | 化合物、光学膜和光学膜的制造方法 |
| JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
| GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
| US20110021531A1 (en) | 2009-07-27 | 2011-01-27 | Chobanian Harry | Oxazole derivatives useful as inhibitors of faah |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| CN102573994B (zh) | 2009-08-06 | 2015-06-24 | 默克专利有限公司 | 双环脲化合物 |
| JP2011042606A (ja) | 2009-08-20 | 2011-03-03 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
| US8669259B2 (en) | 2009-08-26 | 2014-03-11 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2010286933A1 (en) | 2009-08-31 | 2012-03-15 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス， インコーポレイテッド | Ｐｉ３キナーゼインヒビターおよびその使用 |
| CA2772989A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| CN102686551B (zh) | 2009-12-01 | 2014-11-12 | 住友化学株式会社 | 环烷二羧酸单酯的制造方法 |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| US8981084B2 (en) | 2010-01-13 | 2015-03-17 | Tempero Pharmaceuticals, Inc. | Oxadiazole HDAC inhibitors |
| AU2011205283B2 (en) | 2010-01-13 | 2014-07-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| RU2012136624A (ru) | 2010-01-28 | 2014-03-10 | Мерк Шарп Энд Домэ Корп. | Фармацевтические композиции для лечения боли и других показаний |
| EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| BR112012023971A2 (pt) | 2010-04-22 | 2016-11-29 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto. |
| JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
| EP2977085A1 (en) | 2010-04-23 | 2016-01-27 | Kineta, Inc. | Diarylpyridine anti-viral compounds |
| US20120142701A1 (en) | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| JP5652011B2 (ja) | 2010-06-10 | 2015-01-14 | 住友化学株式会社 | 光学フィルム |
| US20130116231A1 (en) | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| JP5862669B2 (ja) | 2010-08-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
| US9006187B2 (en) | 2010-09-10 | 2015-04-14 | Green Cross Corporation | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| JP2014505041A (ja) | 2010-12-23 | 2014-02-27 | ソルヴェイ（ソシエテ アノニム） | トリスホモレプティック金属錯体のｆａｃ異性体の調製 |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
| CN102675289B (zh) | 2011-03-18 | 2014-11-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物 |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013042139A1 (en) | 2011-09-23 | 2013-03-28 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| SG10202103278TA (en) | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
-
2014
- 2014-10-14 ES ES14790936.0T patent/ES2670550T3/es active Active
- 2014-10-14 WO PCT/US2014/060412 patent/WO2015057655A1/en not_active Ceased
- 2014-10-14 RU RU2016118624A patent/RU2671496C2/ru active
- 2014-10-14 KR KR1020167009292A patent/KR102365952B1/ko active Active
- 2014-10-14 AU AU2014334551A patent/AU2014334551B2/en active Active
- 2014-10-14 JP JP2016516866A patent/JP6483666B2/ja active Active
- 2014-10-14 BR BR112016008378-4A patent/BR112016008378B1/pt active IP Right Grant
- 2014-10-14 CN CN201480056216.8A patent/CN105636945B/zh active Active
- 2014-10-14 CA CA2920791A patent/CA2920791C/en active Active
- 2014-10-14 CN CN201710963307.5A patent/CN107935988A/zh active Pending
- 2014-10-14 US US14/908,164 patent/US9663486B2/en active Active
- 2014-10-14 EP EP14790936.0A patent/EP3057948B1/en active Active
- 2014-10-14 MX MX2016004629A patent/MX363708B/es unknown
-
2016
- 2016-02-03 IL IL243926A patent/IL243926B/en active IP Right Grant
-
2019
- 2019-06-02 IL IL267031A patent/IL267031B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN107935988A (zh) | 2018-04-20 |
| AU2014334551A1 (en) | 2016-02-25 |
| IL243926A0 (en) | 2016-04-21 |
| BR112016008378A2 (https=) | 2017-10-03 |
| US9663486B2 (en) | 2017-05-30 |
| RU2016118624A3 (https=) | 2018-04-25 |
| IL267031B (en) | 2021-05-31 |
| BR112016008378B1 (pt) | 2022-11-08 |
| MX2016004629A (es) | 2016-08-01 |
| KR102365952B1 (ko) | 2022-02-22 |
| RU2671496C2 (ru) | 2018-11-01 |
| US20160176841A1 (en) | 2016-06-23 |
| AU2014334551B2 (en) | 2018-05-10 |
| EP3057948B1 (en) | 2018-03-14 |
| CN105636945A (zh) | 2016-06-01 |
| CA2920791C (en) | 2021-11-16 |
| CN105636945B (zh) | 2017-11-17 |
| MX363708B (es) | 2019-03-29 |
| CA2920791A1 (en) | 2015-04-23 |
| RU2016118624A (ru) | 2017-11-17 |
| JP2016539079A (ja) | 2016-12-15 |
| JP6483666B2 (ja) | 2019-03-13 |
| EP3057948A1 (en) | 2016-08-24 |
| KR20160068775A (ko) | 2016-06-15 |
| IL267031A (en) | 2019-07-31 |
| WO2015057655A1 (en) | 2015-04-23 |
| ES2670550T3 (es) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905393B (en) | Selectively substituted quinoline compounds | |
| IL267031B (en) | Selectively converted quinoline compounds | |
| GB201309085D0 (en) | Compounds | |
| AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201302927D0 (en) | Compounds | |
| GB201311951D0 (en) | Compounds | |
| GB201309508D0 (en) | Compounds | |
| GB201317619D0 (en) | Compounds | |
| GB201319363D0 (en) | Compounds | |
| AP2015008699A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201312901D0 (en) | Compounds | |
| EP2948457A4 (en) | COMPOUNDS | |
| GB201306794D0 (en) | Compounds | |
| GB201318461D0 (en) | Compounds | |
| GB201316014D0 (en) | Compounds | |
| GB201310460D0 (en) | Compounds | |
| GB201321553D0 (en) | Compounds | |
| GB201321283D0 (en) | Compounds | |
| GB201318143D0 (en) | Compounds | |
| GB201317118D0 (en) | Compounds | |
| GB201316717D0 (en) | Compounds | |
| GB201315253D0 (en) | Compounds | |
| GB201314700D0 (en) | Compounds | |
| GB201314681D0 (en) | Compounds | |
| GB201311943D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |